Advertisement

Topics

Spain's Almirall warns of delay in approval for psoriasis drug

09:47 EST 14 Nov 2017 | Reuters

(Reuters) - Spanish pharma company Almirall said on Tuesday it expects the launch of psoriasis treatment drug, Tildrakizumab, in Europe to get delayed by at least six months due to regulatory hurdles.

Original Article: Spain's Almirall warns of delay in approval for psoriasis drug

NEXT ARTICLE

More From BioPortfolio on "Spain's Almirall warns of delay in approval for psoriasis drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...